WO1991007967A3 - Method of preventing or limiting reperfusion damage - Google Patents

Method of preventing or limiting reperfusion damage

Info

Publication number
WO1991007967A3
WO1991007967A3 PCT/EP1990/001985 EP9001985W WO9107967A3 WO 1991007967 A3 WO1991007967 A3 WO 1991007967A3 EP 9001985 W EP9001985 W EP 9001985W WO 9107967 A3 WO9107967 A3 WO 9107967A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
reperfusion
heart
alkylpiperazinealkanamide
limiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1990/001985
Other languages
French (fr)
Other versions
WO1991007967A2 (en
Inventor
Belle Herman Van
Laerhoven Willy J C Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to SU905001085A priority Critical patent/RU2093156C1/en
Priority to CA002044143A priority patent/CA2044143C/en
Priority to DE69007471T priority patent/DE69007471T2/en
Priority to AT90917677T priority patent/ATE102831T1/en
Publication of WO1991007967A2 publication Critical patent/WO1991007967A2/en
Priority to NO912511A priority patent/NO304519B1/en
Publication of WO1991007967A3 publication Critical patent/WO1991007967A3/en
Priority to FI913433A priority patent/FI109694B/en
Anticipated expiration legal-status Critical
Priority to HK115095A priority patent/HK115095A/en
Priority to NO19982078A priority patent/NO311701B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Protection Of Pipes Against Damage, Friction, And Corrosion (AREA)
  • Dicing (AREA)
  • Branch Pipes, Bends, And The Like (AREA)
  • Golf Clubs (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Paper (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

The use of an N-alkylpiperazinealkanamide for preventing and/or limiting reperfusion damage upon reperfusion of an organ or muscular tissue, particularly in a patient undergoing thrombolysis or reperfusion of the heart after open heart surgery or after receiving a donor heart. The use of an N-alkylpiperazinealkanamide for preventing and/or limiting reperfusion damage upon reperfusion of a transplanted heart. The use of an N-alkylpiperazinealkanamide for storing a heart for transplantation for at least 24 hours in a cold cardioplegic solution. Compositions comprising an effective reperfusion damage preventing and/or limiting amount of an N-aryl-piperazinealkanamide derivative and optionally further comprising a thrombolytic agent and/or cyclodextrin or an ether derivative thereof. Processes for preparing such compositions. Novel N-alkylpiperazinealkanamide compounds and a process for preparing said compounds.
PCT/EP1990/001985 1989-11-22 1990-11-19 Method of preventing or limiting reperfusion damage Ceased WO1991007967A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SU905001085A RU2093156C1 (en) 1989-11-22 1990-11-19 L-(-)-2-(aminocarbonyl)-n-(4-amino-2,6-dichlorophenyl)-4-[5,5- -bis-(4-fluorophenyl)-pentyl]-1-piperazine acetamide, its pharmaceutically acceptable salt or hydrate, a method of its synthesis and an agent for donor heart storage
CA002044143A CA2044143C (en) 1989-11-22 1990-11-19 Method of preventing or limiting reperfusion damage
DE69007471T DE69007471T2 (en) 1989-11-22 1990-11-19 METHOD FOR PREVENTING OR LIMITING REPERFUSION DAMAGE.
AT90917677T ATE102831T1 (en) 1989-11-22 1990-11-19 METHODS TO PREVENT OR LIMIT REPERFUSION INJURY.
NO912511A NO304519B1 (en) 1989-11-22 1991-06-26 Preparation of (1) - (-) - 2- (aminocarbonyl) -N- (4-amino-2,6-dichlorophenyl) -4- [5,5-bis (4-fluorophenyl) pentyl] -1-piperazine acetamide
FI913433A FI109694B (en) 1989-11-22 1991-07-16 Process for the preparation of a therapeutically useful (1) - (-) - 2- (aminocarbonyl) -N- (4-amino-2,6-dichlorophenyl) -4- [5,5-bis (4-fluorophenyl) pentyl] -1-piperazineacetamide
HK115095A HK115095A (en) 1989-11-22 1995-07-13 Method of preventing or limiting reperfusion damage
NO19982078A NO311701B1 (en) 1989-11-22 1998-05-07 Method of protecting a donor heart for transplantation and using an N-aryl-piperazine alkanamide compound for this purpose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44014289A 1989-11-22 1989-11-22
US440,142 1989-11-22
SG118494A SG118494G (en) 1989-11-22 1994-08-20 Method of preventing or limiting reperfusion damage

Publications (2)

Publication Number Publication Date
WO1991007967A2 WO1991007967A2 (en) 1991-06-13
WO1991007967A3 true WO1991007967A3 (en) 1991-07-11

Family

ID=26664237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1990/001985 Ceased WO1991007967A2 (en) 1989-11-22 1990-11-19 Method of preventing or limiting reperfusion damage

Country Status (22)

Country Link
EP (2) EP0577171B1 (en)
JP (1) JP2574585B2 (en)
KR (1) KR0165686B1 (en)
AT (2) ATE213943T1 (en)
AU (1) AU632888B2 (en)
CA (1) CA2044143C (en)
CY (1) CY1869A (en)
DE (2) DE69033926T2 (en)
DK (2) DK0577171T3 (en)
ES (2) ES2053208T3 (en)
FI (1) FI109694B (en)
HK (1) HK115095A (en)
HU (1) HU215847B (en)
IE (1) IE65121B1 (en)
IL (1) IL96390A (en)
NO (2) NO304519B1 (en)
NZ (1) NZ236168A (en)
PT (2) PT95959B (en)
RU (1) RU2093156C1 (en)
SG (1) SG118494G (en)
WO (1) WO1991007967A2 (en)
ZA (1) ZA909345B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202266D0 (en) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab NOVEL PIPERAZINE CARBOXAMIDES
SE9504661D0 (en) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US6596706B1 (en) * 1997-11-07 2003-07-22 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
SE9904674D0 (en) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904673D0 (en) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (en) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
NZ539828A (en) 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
SE0203303D0 (en) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (en) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (en) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
KR101234421B1 (en) 2004-08-02 2013-02-18 아스트라제네카 아베 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
FR2946340B1 (en) 2009-06-05 2011-06-24 Galderma Res & Dev NOVEL N-PHENYL ACETAMIA, INHIBITORS OF ENZYME SOAT-1, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME
KR101900124B1 (en) 2014-06-25 2018-09-18 전남대학교산학협력단 Compositon for abalone exfoliation agent
KR101644299B1 (en) 2014-07-22 2016-08-02 주식회사 엔바이로젠 Compositon for abalone exfoliation agent comprising schizandra chinensis extract and allilum hookeri extract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068544A2 (en) * 1981-06-23 1983-01-05 Janssen Pharmaceutica N.V. Novel N-aryl-piperazinealkanamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068544A2 (en) * 1981-06-23 1983-01-05 Janssen Pharmaceutica N.V. Novel N-aryl-piperazinealkanamides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Br. J. Pharmacol, vol. 99, Proc. Suppl., 1990, (GB), C.L. Wainwright et al.: "The effects of a nkucleoside transport inhibitor, R75231, on ischaemic arrhythmias in anaesthetised pigs" *
European Journal of Pharmacology - Molecular Pharmacology Section, vol. 172, 1989, Elsevier Science Publishers B.V. (Biomedical Division), (Amsterdam, NL), A.P. IJzerman et al.: "Inhibition or nucleoside transport by a new series of compounds related to lidoflazine and mioflazine", pages 273-281 *
J. Mol. Cell. Cardiol., vol. 21, suppl. 2, 1989, (London, GB), H. van Belle et al.: "Normothermic global ischemia in the isolated working rabbit heart the effect of different drugs on functional recovery and on the release of inarganic phosphate lactic acid nucleosides and norepinephrine", page *

Also Published As

Publication number Publication date
KR0165686B1 (en) 1999-01-15
CY1869A (en) 1996-04-05
HU215847B (en) 1999-04-28
ES2173883T3 (en) 2002-11-01
NO982078D0 (en) 1998-05-07
HU9102436D0 (en) 1991-12-30
DE69033926T2 (en) 2002-10-24
JP2574585B2 (en) 1997-01-22
DE69007471T2 (en) 1994-06-23
ATE213943T1 (en) 2002-03-15
PT95959B (en) 1998-08-31
FI913433A0 (en) 1991-07-16
PT102145B (en) 2002-06-28
NO912511D0 (en) 1991-06-26
DE69007471D1 (en) 1994-04-21
DK0455789T3 (en) 1994-04-05
NO982078L (en) 1991-08-26
ATE102831T1 (en) 1994-04-15
DE69033926D1 (en) 2002-04-11
IL96390A0 (en) 1991-08-16
FI109694B (en) 2002-09-30
HK115095A (en) 1995-07-21
EP0577171A3 (en) 1994-06-29
IL96390A (en) 1995-06-29
EP0577171A2 (en) 1994-01-05
WO1991007967A2 (en) 1991-06-13
SG118494G (en) 1994-11-25
NZ236168A (en) 1993-05-26
RU2093156C1 (en) 1997-10-20
PT102145A (en) 1999-10-29
EP0577171B1 (en) 2002-03-06
ES2053208T3 (en) 1994-07-16
AU632888B2 (en) 1993-01-14
NO311701B1 (en) 2002-01-14
NO304519B1 (en) 1999-01-04
IE65121B1 (en) 1995-10-04
CA2044143C (en) 2002-11-19
AU6876391A (en) 1991-06-26
NO912511L (en) 1991-08-26
EP0455789B1 (en) 1994-03-16
CA2044143A1 (en) 1991-05-23
PT95959A (en) 1991-09-13
EP0455789A1 (en) 1991-11-13
HUT58709A (en) 1992-03-30
KR920700644A (en) 1992-08-10
ZA909345B (en) 1992-08-26
IE904209A1 (en) 1991-05-22
DK0577171T3 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
CA2044143A1 (en) Method of preventing or limiting reperfusion damage
EP0800765A3 (en) A method for preparing organs for long-term preservation and transplantation
EP1637037A3 (en) Method for processing and preserving collagen-based tissues for transplantation
Kononas et al. The fate of suctioned and surgically removed fat after reimplantation for soft-tissue augmentation: a volumetric and histologic study in the rabbit
CA2182814A1 (en) Cryopreservation of Cultured Tissue Equivalents
DE69129112T2 (en) Cryopreservation of cultivated epithelial tissues
DE69232065T2 (en) METHOD FOR PREPARING TISSUE FOR TRANSPLANTATION
WO2002032225A3 (en) Method of cryopreservation of tissues or organs other than a blood vessel by vitrification
GR3018876T3 (en) Method of revitalizing cells prior to cryopreservation
US4167945A (en) Method for enhancing the healing of grafted tissue
US4217890A (en) Surgical sling for positioning a harvested kidney during surgical reattachment
AU4844890A (en) Method and apparatus for the rapid thawing of cryopreserved blood, blood components, and tissue
CA2105478A1 (en) Implantation tissue and treatment and use methods
SG106553A1 (en) Method and package design for cryopreservation and storage of cultured tissue equivalents
CA2147281A1 (en) Method and compositions for removing an alginate from a cutaneous substrate
CA2382207C (en) Method for dehydrating biological tissue for producing preserved transplants
AU3969989A (en) Method of preserving organs
WO2002024244A3 (en) Method of preparing and processing transplant tissue
EP2364708A3 (en) Pharmaceutical composition comprising a ClC-2 channel opener
EP0381514A3 (en) Use of N-methyl-sphingosine as inhibitor of cell growth
HK1041442A1 (en) Composition and method for improving function of embryonic kidney transplants
CA2089336A1 (en) Method for processing and preserving collagen-based tissues for transplantation
Basile Inhibition of proline-hydroxyproline metabolism and phenovariation of Scapania nemorosa
US5700241A (en) Cross-sectional tissue textured surfaces
SU1407469A1 (en) Method of preserving large dura mater

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1990917677

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2044143

Country of ref document: CA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PAT.BUL.13/91, UNDER PUBLISHED REPLACE "A1" BY "A2"

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: TITLE SUBSTITUTED FOR CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 913433

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1990917677

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990917677

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 913433

Country of ref document: FI